The company’s lead drug candidate, MIV-818, is a liver cancer targeted prodrug that Medivir is looking to develop alone in the USA and the EU and through partnerships elsewhere. Swedish ...

Since 2008, the FDA has approved over 30 prodrugs, and approximately 10% of all marketed drugs worldwide can be considered prodrugs. Consequently, the success of prodrug strategies are very powerful ...